Article Metrics


Online attention

Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors

DOI: 10.1016/j.bmc.2020.115815 DOI Help

Authors: Sébastien L. Degorce (AstraZeneca) , Anna Aagaard (AstraZeneca) , Rana Anjum (AstraZeneca) , Iain A. Cumming (AstraZeneca) , Coura R. Diène (AstraZeneca) , Charlene Fallan (AstraZeneca) , Tony Johnson (AstraZeneca) , Karl-johan Leuchowius (AstraZeneca) , Alexandra L. Orton (AstraZeneca) , Stuart Pearson (AstraZeneca) , Graeme R. Robb (AstraZeneca) , Alan Rosen (AstraZeneca) , Graeme B. Scarfe (AstraZeneca) , James S. Scott (AstraZeneca) , James M. Smith (AstraZeneca) , Oliver R. Steward (AstraZeneca) , Ina Terstiege (AstraZeneca) , Michael J. Tucker (AstraZeneca) , Paul Turner (AstraZeneca) , Stephen D. Wilkinson (AstraZeneca) , Gail L. Wrigley (AstraZeneca) , Yafeng Xue (AstraZeneca)
Co-authored by industrial partner: Yes

Type: Journal Paper
Journal: Bioorganic & Medicinal Chemistry , VOL 28

State: Published (Approved)
Published: December 2020

Abstract: In this article, we report our efforts towards improving in vitro human clearance in a series of 5-azaquinazolines through a series of C4 truncations and C2 expansions. Extensive DMPK studies enabled us to tackle high Aldehyde Oxidase (AO) metabolism and unexpected discrepancies in human hepatocyte and liver microsomal intrinsic clearance. Our efforts culminated with the discovery of 5-azaquinazoline 35, which also displayed exquisite selectivity for IRAK4, and showed synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with the covalent BTK inhibitor acalabrutinib.

Journal Keywords: IRAK4; DLBCL; 5-Azaquinazoline; Aldehyde oxidase

Subject Areas: Chemistry, Biology and Bio-materials, Medicine

Instruments: I03-Macromolecular Crystallography